Abstract
The use of biologic agents has revolutionized the management of rheumatoid arthritis (RA) in the past two decades. These biologic agents directly target molecules and cells involved in the pathogenesis of RA. Biologic agents indeed lead to a better prognosis and clinical remission in patients with RA, especially in patients who are not well-controlled with traditional disease-modifying anti-rheumatic drugs (DMARDs). Currently, five TNF inhibitors (infliximab, etanercept, adalimumab, golimumab and certolizumab pegol), an IL-6 receptor antagonist (tocilizumab), an IL-1 receptor antagonist (anakinra), a B cell depleting agent (rituximab) and a T cell co-stimulation inhibitor (abatacept) have been approved for the treatment of RA. With the increased understanding of the pathogenic mechanisms of RA and advantages in manufacturing biotechnology of pharmaceutical companies, a series of novel biologic therapeutic approaches are being developed. In the present paper, we will summarize the biologic agents currently available to treat RA, and the prospective biologic therapies that might be used in the management of RA in future.
Keywords: Biologic therapy, cell-targeted therapy, cytokine-targeted therapy, rheumatoid arthritis.
Current Pharmaceutical Biotechnology
Title:The Use of Biologic Therapies in the Treatment of Rheumatoid Arthritis
Volume: 15 Issue: 6
Author(s): Dashan Wang, Yan Li, Yuan Liu and Guixiu Shi
Affiliation:
Keywords: Biologic therapy, cell-targeted therapy, cytokine-targeted therapy, rheumatoid arthritis.
Abstract: The use of biologic agents has revolutionized the management of rheumatoid arthritis (RA) in the past two decades. These biologic agents directly target molecules and cells involved in the pathogenesis of RA. Biologic agents indeed lead to a better prognosis and clinical remission in patients with RA, especially in patients who are not well-controlled with traditional disease-modifying anti-rheumatic drugs (DMARDs). Currently, five TNF inhibitors (infliximab, etanercept, adalimumab, golimumab and certolizumab pegol), an IL-6 receptor antagonist (tocilizumab), an IL-1 receptor antagonist (anakinra), a B cell depleting agent (rituximab) and a T cell co-stimulation inhibitor (abatacept) have been approved for the treatment of RA. With the increased understanding of the pathogenic mechanisms of RA and advantages in manufacturing biotechnology of pharmaceutical companies, a series of novel biologic therapeutic approaches are being developed. In the present paper, we will summarize the biologic agents currently available to treat RA, and the prospective biologic therapies that might be used in the management of RA in future.
Export Options
About this article
Cite this article as:
Wang Dashan, Li Yan, Liu Yuan and Shi Guixiu, The Use of Biologic Therapies in the Treatment of Rheumatoid Arthritis, Current Pharmaceutical Biotechnology 2014; 15 (6) . https://dx.doi.org/10.2174/138920101506140910150612
DOI https://dx.doi.org/10.2174/138920101506140910150612 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Multi-target Activities of Selected Alkaloids and Terpenoids
Mini-Reviews in Organic Chemistry The Role of AGEs in Cardiovascular Disease
Current Pharmaceutical Design B Cell Modulation Strategies in Autoimmunity: The SLE Example
Current Pharmaceutical Design Computation-Based Design and Engineering of Protein and Antibody Therapeutics
Drug Design Reviews - Online (Discontinued) Nanocarriers in the Delivery of Hydroxychloroquine to the Respiratory System: An Alternative to COVID-19
Current Drug Delivery Expanding the Therapeutic Potential of Statins by Means of Nanotechnology Enabled Drug Delivery Systems
Current Topics in Medicinal Chemistry Chemical Space of FLT3 Inhibitors as Potential Anti-AML Drugs
Recent Patents on Anti-Cancer Drug Discovery Can Unconventional Exercise be Helpful in the Treatment, Management and Prevention of Osteosarcopenic Obesity?
Current Aging Science Impact of MCP -1 in Atherosclerosis
Current Pharmaceutical Design Emerging Drug Therapies and Site-Specific Interventions for Autoimmune Hepatitis
Medicinal Chemistry Reviews - Online (Discontinued) High-throughput Genotyping Methods for Pharmacogenomic Studies
Current Pharmacogenomics Targeting IL-17 and IL-23 in Immune Mediated Renal Disease
Current Medicinal Chemistry Novel Insights into the Pathogenesis of Osteoarthritis
Current Rheumatology Reviews Gastroduodenal Safety of Cyclooxygenase-2 Inhibitors
Current Pharmaceutical Design Hormetic Potential of Sulforaphane (SFN) in Switching Cells’ Fate Towards Survival or Death
Mini-Reviews in Medicinal Chemistry Potential Factors Induced by Filoviruses that Lead to Immune Supression
Current Molecular Medicine Design of New Oxazaphosphorine Anticancer Drugs
Current Pharmaceutical Design ADAM17 as a Therapeutic Target in Multiple Diseases
Current Pharmaceutical Design Biological Therapies of Autoimmune Diseases
Current Drug Targets - Inflammation & Allergy Clinical and Pharmacological Aspects of Inflammatory Demyelinating Diseases in Childhood: An Update
Current Neuropharmacology